An asset purchase agreement has been signed with Dexcel Pharma USA, which will acquire the full rights to Zubsolv® in the US, at a purchase price of USD 91 million plus the value of inventory at closi ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback